NanoSphere Health Sciences: Advancing the Industry with Breakthrough Cannabinoid Delivery

Ryan Allway May 10th, 2018 Exclusive, News, Top News

The cannabis industry is projected to exceed $50 billion over the coming years, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis. While many investors are focused on cultivation and retail, there are several companies focused on solving key problems facing the industry that provide unique investment opportunities. A great example of an upcoming sector is advanced cannabinoid delivery, where there is a lot of room for improvement from current mainstream methods of consumption.

NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is a biotech firm that has invented a next-generation, patented delivery platform – called the NanoSphere Delivery System™ – to vastly improve the delivery of a range of active compounds. The technology has the potential to reshape and reimagine industries such as pharmaceuticals, nutraceuticals, cosmeceuticals and animal health.

Management recognized delivery needs within the burgeoning cannabis industry two years ago, and today the company’s cannabis brand Evolve Formulas has products in over 100 dispensaries in Colorado. With plans to expand the market far beyond Colorado, NanoSphere offers a commercial-stage opportunity in a crucial subset of the industry.

Cannabinoid Delivery Challenges

Cannabis has been legalized for medical use across 29 states and for recreational use across nine states. Despite these regional regulatory wins, cannabis remains illegal on a federal level. While advocates have been extremely successful in raising awareness of the drug’s potential to treat numerous medical conditions, cannabis has been a challenge for medical professionals and public health officials.

The lack of standardized doses or delivery methods make it difficult for physicians to accurately prescribe the drug even if they know that it may be safe and efficacious. For instance, researchers have found that the bioavailability of cannabinoids differs greatly between individuals and delivery methods. Bioavailability for smoking alone ranged between two percent and 56 percent due to intra and inter-subject variability.

Smoking cannabis has also become a major public health concern. Burning any kind of plant material is well known to release many toxic chemicals, including volatile organic compounds (VOCs) and noxious gases, into the air. Individuals consuming cannabis can face many of the same symptoms of lung damage as tobacco smokers, while second-hand smoke is a major issue. This has led to growing demand for alternative delivery systems to mitigate these harmful effects. Still, with the plant federally illegal, these issues remain difficult to address from both an R&D and a regulatory perspective.

But, the good news is that change may finally be on the way. President Trump promised Republican Sen. Cory Gardner (R-CO) that the Department of Justice’s rescission of the Cole Memo would not impact Colorado’s legal industry, joining many other Republicans in putting states’ rights ahead of federal prohibition. At the same time, Senate Minority Leader Chuck Schumer suggested that he would be drafting a bill to remove marijuana from the Controlled Substances Act. That news surfaced shortly after Sen. Bernie Sanders (I-VT) announced that he would co-sponsor Sen. Cory Booker’s (D-NJ) Marijuana Justice Act.

NanoSphere Delivery System™

NanoSphere Health Sciences’ NanoSphere Delivery System™ is designed to increase the bioavailability of hard-to-absorb nutrients, like fat-soluble vitamins, fatty acids, minerals, botanical extracts, and phytochemicals. The technology was initially designed for nutraceuticals, enabling consumers to realize more bioavailability than traditional methods without the need to swallow capsules or take tinctures.

The NanoSphere Delivery System™ works by nano-encapsulating active ingredients in lipid nanoparticles, enabling them to pass through the skin and mucosa into the bloodstream and cells. This significantly increases the bioavailability and bioactivity of these compounds compared to exposing them to the gastrointestinal tract where they are subject to first-pass metabolism in the liver. The enhanced bioavailability and bioactivity leads to better outcomes for consumers, such as rapid action and less adverse side effects.

On March 27, the company announced that it was granted U.S. Patent No. 9,925.149 covering the core technology behind the NanoSphere Delivery System™. The addition to the company’s intellectual property portfolio protects the invention for a prolonged period of time and opens the door to royalty income through potential and current licensing opportunities down the road across cannabinoid, pharmaceutical, nutraceutical, cosmeceutical, and other markets.

Applying the Technology

Since entering the cannabis market, the company has developed transdermal, intraoral, and intranasal products utilizing the NanoSphere Delivery System™ to transport cannabinoids directly into the bloodstream and to CB1 and CB2 receptors. The incorporation of the breakthrough technology enables precise, measurable doses and rapid absorption compared to other delivery methods. As a result, these products have become a valuable option for medical cannabis patients.

The company’s pioneering cannabis product, Transdermal NanoSerum™, is now available in 5 ml and 10 ml pen sizes in over 100 medical and recreational dispensaries in Colorado. The ingredients in NanoSerum™ are 100 percent natural and contaminant-free, made from biocompatible, biodegradable, and non-toxic materials, which sets it apart from competing products.

Management plans to significantly increase the footprint of NanoSerum™ and its other products in the United States and around the world over the near-term.

Looking Ahead

NanoSphere Health Sciences Inc (CSE: NSHS) (OTC: NSHSF) represents a unique investment opportunity targeting both the medical and recreational cannabis markets. Using its industry-first NanoSphere Delivery System™ technology, the company delivers cannabinoids into circulation within minutes for fast-acting, effective relief from pain, inflammation, and anxiety. The same technology is also being applied to recreational markets to help produce a better high.

In addition to over 100 dispensaries in Colorado, the company signed a recent licensing agreement in California and plans to launch its products into that market this summer. Management is also in negotiations with several other potential partners in the United States and around the world. Given the significant upcoming catalysts, NanoSphere Health Sciences is a stock to watch closely.

For more information, visit the company’s website at www.nanospherehealth.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.